The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage ...

Summit Therapeutics (NASDAQ: SMMT) recently reported Ivonescimab’s Phase 3 results from study conducted in China that showed ...

Those following along with Summit Therapeutics Inc. (NASDAQ:SMMT) will no doubt be intrigued by the recent purchase of shares by Robert Duggan, Co-CEO & Executive Chairman of the company, who spent a ...

Summit Therapeutics' ivonescimab shows a significant PFS improvement over pembrolizumab in NSCLC. Read why I'm bearish on ...

Summit Therapeutics SMMT has outperformed the market over the past 5 years by 73.1% on an annualized basis producing an ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $14 ...

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...

Summit Therapeutics presents updated Ivonescimab data from phase II studies at ESMO 2024 annual meeting: Miami Wednesday, September 18, 2024, 15:00 Hrs [IST] Summit Therapeutics I ...

Summit Therapeutics Inc. (SMMT) announced Thursday proceeds of approximately $235 million in a fundraise led by insiders & biopharma ...